Invited Commentary

Place in Therapy for Liraglutide and Saxagliptin for Type 2 Diabetes and FDA Liraglutide Warning

Authors: Michael Shawn McFarland, PharmD, Meghan Brock, PharmD, Casey Ryals, PharmD

Abstract

The Food and Drug Administration (FDA) issued a reminder through the MedWatch program to providers on June 13, 2011 that highlighted the risk of thyroid carcinoma and acute pancreatitis with the use of liraglutide (Victoza). This was prompted by a letter from Novo Nordisk, the maker of liraglutide, after an assessment revealed that not all primary care providers were aware of these serious conditions.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. McFarland M, Brock M, Ryals C. Place in therapy for liraglutide and saxagliptin for type 2 diabetes. South Med J 2011;104:426-439.
 
2. Parks M, Rosenbaugh C. Weighing the risks and benefits of liraglutide-the FDA's review of a new antidiabetic therapy. N Engl J Med 2010;362:774-777.
 
3. Marre M, Shaw J, Brandle M, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulfonylurea over 26 weeks produces greater improvements in glycemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabetic Med 2009;26:268-278.
 
4. Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes (the LEAD-2 Study). Diabetes Care2009;32:84-90.
 
5. Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomized, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009;373:473-481.
 
6. Zinman B, Gerich J, Buse JB, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met-TZD). Diabetes Care 2009;32:1224-1230.
 
7. Russell-Jones D, Vaag A, Schmitz O, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus: a randomised controlled trial (LEAD-5 Met+ SU). Diabetologia 2009;52:2046-2055.
 
8. Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomized, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009;374:39-47.